This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases

This study has been terminated.
(Accrual was met.)
Sponsor:
Information provided by (Responsible Party):
Scott Soltys, Stanford University
ClinicalTrials.gov Identifier:
NCT00928226
First received: June 23, 2009
Last updated: January 5, 2017
Last verified: January 2017
  Purpose
We hope to determine the maximum tolerated dose of 3 session (i.e., treatment) stereotactic radiosurgery to treat brain metastases greater than 4.2 cm3 in size. By increasing radiation dose, we will determine if there is a better outcome without greater toxicity (side effects) for patients.

Condition Intervention Phase
Brain Cancer Neoplasm Metastasis Cancer of Brain and Nervous System Metastatic Malignant Neoplasm to Brain Procedure: Fractionated Stereotactic Radiosurgery Device: Linear accelerator Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases

Further study details as provided by Scott Soltys, Stanford University:

Primary Outcome Measures:
  • Determine the maximum tolerated dose (MTD) of SRS given in 3 fractions for brain metastases 4.2 - 14.1 cm3 and 14.2 - 33.5 cm3. [ Time Frame: 60 days (per patient) ]

Secondary Outcome Measures:
  • Determine the local control rate as assessed on MRI and clinical exam [ Time Frame: 3, 6, 9, and 12 months following treatment ]
  • Determine short term and long term adverse effects [ Time Frame: 60 days (per patient) ]
  • Determine the distant intra-cranial control rate [ Time Frame: 3, 6, 9, and 12 months following treatment ]
  • Assess the patients health related quality of life [ Time Frame: 1, 3, 6, 9, and 12 months following treatment ]
  • Determine the overall survival rate [ Time Frame: Until death ]

Enrollment: 120
Study Start Date: April 2009
Estimated Study Completion Date: March 2017
Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 4.2 - 14.1 cm3 brain metastasis following surgical resection Procedure: Fractionated Stereotactic Radiosurgery
Standard of care
Other Name: Cyberknife surgery
Device: Linear accelerator
Standard of care
Other Names:
  • linear particle accelerator
  • linac
Experimental: 14.2 - 33.5 cm3 brain metastasis following surgical resection Procedure: Fractionated Stereotactic Radiosurgery
Standard of care
Other Name: Cyberknife surgery
Device: Linear accelerator
Standard of care
Other Names:
  • linear particle accelerator
  • linac
Experimental: 4.2 - 14.1 cm3 unresectable brain metastasis
4.2-14.1 cm3 unresectable brain metastasis treated with SRS alone
Procedure: Fractionated Stereotactic Radiosurgery
Standard of care
Other Name: Cyberknife surgery
Device: Linear accelerator
Standard of care
Other Names:
  • linear particle accelerator
  • linac
Experimental: 14.2 - 33.5 cm3 unresectable brain metastasis
14.2 - 33.5 cm3 unresectable brain metastasis treated with SRS alone.
Procedure: Fractionated Stereotactic Radiosurgery
Standard of care
Other Name: Cyberknife surgery
Device: Linear accelerator
Standard of care
Other Names:
  • linear particle accelerator
  • linac

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients age 18 years and older with pathologically proven solid tumor malignancy and 1 to 4 brain metastases, one of which is 4.2 - 33.5 cm^3.
  • Systemic therapy: Prior cytoxic systemic therapy must be completed >= 5 days prior to radiosurgery. No concurrent cytoxic systemic therapy along with SRS. Cytoxic systemic therapy to start >= 5 days after the completion of SRS.
  • Prior surgery or SRS is allowed as long as the target metastatic lesion in this study has not previously been treated with SRS.
  • Patient must exhibit the ability to understand and the willingness to sign a written informed consent.
  • Life expectancy of at least 12 weeks.

Exclusion Criteria:

  • Patients who have previously been treated with whole brain irradiation.
  • Patients whose metastatic lesion in question had previously been treated with SRS.
  • The patient has greater than 4 total brain metastases at the time of initial evaluation.
  • Pediatric patients (age <18), pregnant women, and patients who are unable to give informed consent will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00928226

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Clara Choi Stanford University
Principal Investigator: Scott Soltys Stanford University
  More Information

Responsible Party: Scott Soltys, Assistant Professor of Radiation Oncology, Stanford University
ClinicalTrials.gov Identifier: NCT00928226     History of Changes
Other Study ID Numbers: IRB-15107
SU-04272009-2418 ( Other Identifier: Stanford University )
BRN0010 ( Other Identifier: OnCore )
Study First Received: June 23, 2009
Last Updated: January 5, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Neoplasms
Neoplasm Metastasis
Brain Neoplasms
Neoplasms, Second Primary
Neoplastic Processes
Pathologic Processes
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on July 19, 2017